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OBJECTIVES We sought to determine if the nitric oxide (NO) donor isosorbide mononitrate (ISMN) (200
mg/kg body weight/day) decreases vascular bioavailability of superoxide in atherosclerosis.
BACKGROUND Vascular oxidative stress limits the bioavailability of endothelial NO and promotes athero-
sclerosis, while NO itself exerts antioxidative effects. It is unknown if therapeutic NO impacts
on vascular oxidative stress in atherosclerosis.
METHODS New Zealand white rabbits (n  10 each group) were fed either normal chow (control),
cholesterol chow (CHOL) (0.75 %), or cholesterol chow enriched with ISMN (CHOL-
ISMN). Rabbits were fed twice daily. After 16 weeks we used aortic segments to measure
vascular superoxide (5-M lucigenin), intimal lesion formation, and vasoreactivity to
acetylcholine (ACH) and ISMN.
RESULTS Plasma cholesterol increased by 40-fold in CHOL and CHOL-ISMN. The plasma
concentration of ISMN in CHOL-ISMN was 1,529  447 ng/ml. Superoxide formation
(control: 228  20 counts/20 min/mg) was strongly enhanced in CHOL (345  46
counts/20 min/mg, p  0.02) but not in CHOL-ISMN (229  23 counts/20 min/mg)
demonstrating antioxidative effects of eccentric ISMN in vivo. In parallel, intima-media
thickness of thoracic aorta (159 4 m in control) was reduced from 645 41 m (CHOL)
to 440  51 m (CHOL-ISMN, p  0.05). Likewise, eccentric ISMN partially restored
vascular responses to the NO donor S-nitroso-N-acetyl-D,L-penicillamine and improved
endothelium-dependent vasorelaxation. The maximal ACH relaxation increased from 26.3
9.6% in CHOL to 49.7  8.1% in CHOL-ISMN; ISMN treatment induced a moderate
nitrate tolerance as evidenced by diminished ISMN-induced vasodilation.
CONCLUSIONS These data suggest that eccentric ISMN can completely inhibit the increase of vascular
bioavailability of superoxide and partially prevent intimal lesion formation and endothelial
dysfunction in hypercholesterolemia. (J Am Coll Cardiol 2004;44:624–31) © 2004 by the
American College of Cardiology Foundationw
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pypercholesterolemia promotes atherosclerosis and is a
ajor risk factor of acute coronary syndromes and cardio-
ascular death. Its pathogenesis is multifactorial and in-
ludes vascular inflammation and increased generation of
ascular superoxide and other reactive oxygen species such
s peroxynitrite, hydroxyl radicals, and hydrogen peroxide
1,2). One of the major consequences of increased vascular
See page 632
ioavailability of superoxide is an impairment of vascular
ndothelial function. This has been initially demonstrated
any years ago (3,4), and evidence for an involvement of
uperoxide in endothelial dysfunction induced by hypercho-
esterolemia in rabbits was provided (5). Today, it is very
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ieraerztliche Hochschule, Hannover, Germany. This study was supported by the
orschschingskommission of the Heinrich-Heine-Universitaet, Project 9772179.
Manuscript received August 29, 2003; revised manuscript received February 13,e004, accepted February 17, 2004.ell-established that the so-called vascular oxidative stress is
ssociated with a variety of cardiovascular diseases such as
oronary artery disease, hypertension, heart failure, and
oninsulin-dependent diabetes mellitus (2).
The mechanism underlying the increased bioavailability
f vascular reactive oxygen species is multifactorial and
nvolves an increased expression and activity of enzymes
enerating oxygen radicals such as NADPH-oxidase, a
ecreased expression and activity of enzymes such as super-
xide dismutase (SOD), which detoxifies reactive oxygen
pecies, and a decreased concentration of cellular antioxi-
ants such as cysteine and glutathione (6). At the same
ime, oxidative stress reduces the bioavailability of vascular
itric oxide (NO) and initiates endothelial dysfunction (7).
hese findings lead to the hypothesis that an imbalanced
eneration of superoxide and NO contributes to the patho-
enesis of cardiovascular diseases. Both radicals are impor-
ant biological mediators that promote pathogenic and
rotective effects in the vasculature, respectively (6,8).
Organic nitrates are a structurally diverse group of com-
ounds that all carry an aliphatic nitrate moiety that is
nzymatically reduced by a flow of three electrons to the
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August 4, 2004:624–31 Eccentric ISMN and Vascular Oxidative Stressitrate nitrogen to generate NO (9,10). This reduction of
he nitrate moiety occurs in many cell types including
ascular smooth muscle and endothelial cells, and it has
een shown that treatment with organic nitrates increases
he NO content of rabbit arteries and veins (11). Although
ntioxidative effects of NO itself have been well-established
n vitro, it is not known if NO donors such as organic
itrates are capable of reducing vascular oxidative stress in
ypercholesterolemia.
We sought to determine if the NO donor isosorbide
ononitrate (ISMN) decreases vascular bioavailability of
uperoxide and endothelial dysfunction in hypercholester-
lemia and investigated the effects of long-term oral ISMN
n changes of vascular reactivity in hypercholesterolemic
abbits. We found that eccentric ISMN completely inhibits
he increase of vascular bioavailability of superoxide and
artially prevents intimal lesion formation and endothelial
ysfunction. These data indicate that eccentric ISMN
ight provide vasoprotection in hypercholesterolemia.
ETHODS
nimals studied. A total of 30 female New Zealand white
abbits (10 to 12 weeks, mean body weight 2,105  47 g)
ere housed individually as described previously (12). Rab-
its were randomly divided in 3 groups of 10 animals and
ere fed either a standard diet (control), a 0.75 % w/w
holesterol diet (CHOL), or a cholesterol diet supple-
ented with ISMN to achieve a daily dosage of 200 mg
SMN/kg body weight ISMN (CHOL-ISMN) for 16
eeks. The dosage of ISMN was given in two identical
ortions in the morning (8:00 AM) and in the early after-
oon (3:00 PM). During the study the animals were super-
ised by a veterinarian. Body weight was determined weekly,
nd plasma cholesterol concentrations were determined
efore and eight weeks after initiation of treatment. Ani-
als were sacrificed 3 h after the last application of ISMN
n the morning.
Permission for this study was provided by the regional
overnment (AZ 23.05-230-3-77/99, AZ 23.05-230-3-52/
9), and the experiments were performed according to the
uidelines for the use of experimental animals as given by
Deutsches Tierschutzgesetz” and the “Guide for the Care
nd Use of Laboratory Animals” of the U.S. National
Abbreviations and Acronyms
cGMP  cyclic guanosine monophosphate
ecSOD  extracellular superoxide dismutase
GCMS  gas chromatography mass spectrometry
GTN  glyceryl mononitrate
ISMN  isosorbide mononitrate
NO  nitric oxide
sGC  soluble guanylyl cyclase
SNAP  S-nitroso-N-acetyl-D,L-penicillamine
SOD  superoxide dismutasenstitutes of Health. masorelaxation studies. Rabbits were anesthetised by in-
ection of a mixture of xylazine (5 mg/kg1) and ketamine
25 mg/kg1) into the tibialis muscle. The animals were
illed by exsanguination in deep anesthesia, and the entire
horacic and abdominal aorta were dissected free. Prepara-
ion of four thoracic ring segments and equilibration was
erformed in Krebs-Henseleit buffer as described previously
12). Function of endothelium was examined by cumulative
ddition of acetylcholine (0.01 to 10 M) after submaximal
recontraction with 0.2 M phenylephrine. This was fol-
owed by a washout and a cumulative application of phen-
lephrine (0.01 to 10 M). Thereafter the aortic rings were
gain rinsed with buffer and divided in subgroups, and the
asorelaxations to different types of NO donors such as
-nitroso-N-acetyl-D,L-penicillamine (SNAP) (1 nM to
0 M) and ISMN (10 nM to 1 mM) were studied by
umulative application after precontraction with phenyleph-
ine (0.2 M); KCl, acetylcholine, phenylephrine, and each
O donor was studied in endothelium intact, and in
ndothelium-denuded thoracic rings from each animal.
etermination of aortic superoxide. Aortic superoxide was
etermined as described previously (13). Briefly, equilibrated
egments of thoracic aorta were incubated at 37°C in albumin-
uffer (pH 7.4) of the following composition (in mM): Na
44.93, K 7.23, Cl 138.77, H2PO4
 4.55, HPO4
2 8.03,
lucose 5.55, and bovine serum albumin (0.1 %, weight/
olume). This buffer was enriched with lucigenin (5 M), and
uperoxide was calculated from chemiluminescence measure-
ents (Picolite A6112 Luminometer, Packard, Downers
rove, Illinois).
etermination of plasma and tissue concentrations of
SMN. Plasma concentrations of ISMN were determined
ith support of ACC GmbH, Leidersbach, Germany. Briefly,
lood samples were taken by punctation of the middle ear
rtery with heparin (15 U/ml) containing syringes 3 h after the
ast morning dose of ISMN. Blood samples were rapidly
entrifuged at 4°C and 1,000 g for 10 min. The supernatant
as frozen at 20°C and stored until use. Vascular concen-
rations of ISMN were determined in frozen aortic rings;
SMN was determined by gas chromatography mass spec-
rometry (GCMS) (HP6890, Hewlett Packard, Waldbronn,
ermany) after liquid-liquid extraction with ethyl acetate.
istologic and histochemical procedures. One aortic
ing (1-cm length) of each rabbit of the three groups was
xed in buffered 4% formalin and embedded ethanol-free in
he water-soluble plastic resin Technovit 7100 (Heraeus-
ulzer, Hanau, Germany) to prevent shrinkage and lipid
xtraction; 4-m sections were stained with 1% toluidine
lue, and intima as well as intima-media thickness were
easured using the image-analyzing system CUE-3 (Olym-
us Ltd., version 4.5, 1993, Hamburg, Germany). For a
etter determination of plaque formation, aorta sections of
ll groups were also stained lipid histochemically with sudan
lack B (saturated in 70% ethanol at 4°C). The measure-
ents were routinely performed in a double-blind experi-
m
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Eccentric ISMN and Vascular Oxidative Stress August 4, 2004:624–31ental approach by a technical assistant that had no
nowledge of the specific scientific background of the study.
ubstances and solutions. S-nitroso-N-acetyl-D,L-
enicillamine was synthesized in our laboratory as described
reviously (14). Isosorbide mononitrate was provided by
chwarz Pharma, Monheim, Germany. All other chemicals
ere obtained from Merck, Darmstadt, Germany, or from
igma, Deisenhofen, Germany, in analytical grade. The
tock solutions of acetylcholine (10 mM), phenylephrine (10
M), and ISMN (100 mM) were prepared in distilled
ater. Solutions of SNAP (200 mM) were prepared in
imethylsulfoxide. All stock solutions were prepared daily,
iluted with Krebs-buffer as required, kept on ice, and
rotected from daylight until use. All concentrations indi-
ated in the text and figures are expressed as final bath
oncentrations.
tatistics. All data were analyzed by standard computer
rograms (GraphPad Prism PC Software, San Diego, Cali-
ornia, version 3.0, analysis of variance [ANOVA]) and are
xpressed as mean values and standard error of the mean
SEM). Significant differences were evaluated using either
npaired two-tailed Student t test or ANOVA with subse-
uent Newman-Keuls multiple comparison test when appro-
riate. A p value 0.05 was considered significant.
ESULTS
ll animals completed the study. Animals of CHOL and
HOL-ISMN showed some hair loss at their feet, neck, and
elly and had an enlarged liver with easily visible yellow fat
eposits. Such deposits also occurred in the skin and the iris.
he increase in body weight observed during the study was
lightly greater in controls (from 2,162 20 g to 3,752 99 g;
 0.003 for comparison of final body weights) compared
ith CHOL (from 2,122  34 g to 3,314  76 g) and
HOL-ISMN (from 1,953 60 to 3,255 67). During the
igure 1. Effect of a four months’ lasting oral treatment with isosorbide
ononitrate (ISMN) on changes of aortic superoxide induced by hyper-
holesterolemia. Given are the cumulative counts/mg tissue measured
uring incubation with 5 M lucigenin. The significant increase of
uperoxide in cholesterol chow group (CHOL) was completely abolished
y treatment with ISMN (*p  0.01 CHOL vs. control and CHOL-
SMN).tudy the plasma concentration of total cholesterol increased in hHOL (from 75  11 mg/dl to 2,133  95 mg/dl) and in
HOL-ISMN (from 72  10 to 2,030  135) but not in
ontrols (from 52 4 mg/dl to 53 4 mg/dl). The plasmatic
oncentration of ISMN in CHOL-ISMN was 1,529  447
g/ml (corresponds to 8 M), and the ISMN concentration in
ashed aortic segments used for superoxide and vasorelaxation
easurements was 53.5  8.4 pmol/g aorta (corresponds to
3.4 nM). Control experiments in rat aorta showed that 65
M ISMN had no effect on the detection of superoxide with
ucigenin as indicated by identical accumulation at rates (in
ounts/mg/min, n  3 each) of 10.4  0.55 (control) and 9.7
0.83 (ISMN).
ascular superoxide. Superoxide in aortic rings was signif-
cantly increased in CHOL compared with controls (Fig. 1).
he mean maximal values were 228  20 counts/20
in/mg in controls and 345  46 counts/20 min/mg in
HOL (p  0.02) confirming that hypercholesterolemia
nduces vascular oxidative stress. In striking contrast, there
as no increase of superoxide in CHOL-ISMN as evi-
enced by the maximal mean value of 229  23 counts/20
in/mg. These data suggest that eccentric ISMN can
ompletely prevent the increase of vascular superoxide in
igure 2. Area of intimal lesions in the aorta stained with sudan IV (black
reas, panels B and C). Given are representative examples of aortic
egments of (A) control, (B) cholesterol chow (CHOL), and (C) choles-
erol chow-isosorbide mononitrate (CHOL-ISMN), and (D) the mean
alues of aortic arch segments of CHOL and CHOL-ISMN (*p 
.0094).ypercholesterolemia.
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August 4, 2004:624–31 Eccentric ISMN and Vascular Oxidative Stresshanges of vascular morphology. Hypercholesterolemia
nduced typical atherosclerotic lesions in the aorta. Macro-
copic inspection (Figs. 2A, 2B, and 2C) showed a strong
taining in CHOL, which was lower in CHOL-ISMN. A
ore detailed microscopic evaluation of cross-sections showed
strong accumulation of lipid-laden cells in the plaques of
HOL that was lower in CHOL-ISMN (data not shown).
easurement of the intima-media thickness in cross-sections
f the aorta (Fig. 3) showed a strong increase in CHOL that
as significantly diminished in CHOL-ISMN suggesting that
ccentric ISMN can reduce the formation of intimal lesions in
xperimental hypercholesterolemia.
ndothelium-dependent vasodilation. In CHOL, relax-
tion of aortic rings induced by 1 M acetylcholine showed
maximum of only 26.3  9.6% (Fig. 4) indicating severe
mpairment of normal endothelial function (controls: 82 
.8%). In striking contrast, endothelium-dependent vasore-
igure 3. Cross-sections of thoracic aortic rings stained with sudan black
to visualize atherosclerotic areas (black areas). Given are representative
xamples of aortic cross-sections (* lumen) of (A) control, (B) cholesterol
how (CHOL), and (C) cholesterol chow-isosorbide mononitrate
CHOL-ISMN), and (D) the mean values of the intima-media thickness
*p  0.001, vs. control, #p  0.001 CHOL-ISMN vs. CHOL).axation in CHOL-ISMN showed a maximum of 49.7  0.1% (p 0.05 vs. CHOL) indicating a reduced endothelial
ysfunction in hypercholesterolemic rabbits treated with
SMN. In addition, there was a significant linear relation-
hip between the maximal relaxation to acetylcholine and
he severity of aortic intimal lesion area in both CHOL (r
igure 4. Effect of a four months’ lasting oral treatment with isosorbide
ononitrate (ISMN) on changes of endothelium-dependent vasorelax-
tion induced by hypercholesterolemia in (A) endothelium-intact aortic
ings. The significant impairment of endothelium-dependent vasodilation
n cholesterol chow (CHOL) as compared with controls was partially
eversed by ISMN (*p  0.001 CHOL vs. CHOL-ISMN; #p  0.001
HOL-ISMN vs. control). In (B) endothelium-denuded rings, acetylcho-
ine induced vasoconstrictions..839, p  0.0001) and CHOL-ISMN (r  0.708, p 
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Eccentric ISMN and Vascular Oxidative Stress August 4, 2004:624–31.0005). However, acetylcholine-induced vasodilation in
HOL-ISMN was still significantly lower as compared
ith controls indicating that ISMN did not completely
nhibit the development of endothelial dysfunction. In
ndothelium-denuded aortic rings, acetylcholine evoked
asoconstrictions only.
O-dependent vasodilation. Hypercholesterolemia in-
uced a decrease of the vasodilator response to the NO
onor SNAP (Fig. 5) as evidenced by a significant rightward
hift of the concentration-reponse curve. This desensitiza-
ion against NO-induced vasodilation in hypercholester-
lemic rabbits was almost completely reversed by ISMN.
he halfmaximal vasodilator concentrations in (logM)
ere 7.43  0.03 in controls, 6.56  0.09 in CHOL, and
.05  0.09 in ISMN-CHOL.
ccurrence of nitrate tolerance. Treatment with eccentric
SMN induced the development of a moderate nitrate
olerance as evidenced by a rightward shift of the concen-
ration response curve for ISMN (Fig. 6). In contrast,
ypercholesterolemia itself did not reduce vasodilation by
SMN. The halfmaximal vasodilator concentrations in
logM) were 5.23  0.03 in controls, 5.08  0.05 in
HOL, and 4.76  0.05 in ISMN-CHOL.
ISCUSSION
he aim of this study was to determine the influence of NO
onors, such as organic nitrates, on vascular oxidative stress
igure 5. Effect of a four months’ lasting oral treatment with isosorbide
ononitrate (ISMN) on changes of vasorelaxations to the nitric oxide
NO) donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) induced by
ypercholesterolemia. The significant reduction of the vascular sensitivity
gainst NO-dependent vasodilation induced by SNAP (rightward-shift,
p  0.0001, control vs. cholesterol chow [CHOL]) was partially reversed
y ISMN (CHOL vs. CHOL-ISMN: #p  0.001).n hypercholesterolemia. Our new finding is that the NO ionor ISMN can completely prevent the increase of vascular
uperoxide induced by hypercholesterolemia. Furthermore,
ccentric ISMN exerted these antioxidative effects despite
he development of moderate nitrate tolerance. Isosorbide
ononitrate treatment was also associated with an improve-
ent of endothelial function and a reduction of vascular
esion formation. These results suggest that long-term
reatment with eccentric ISMN may offer vasoprotection in
ypercholesterolemia.
There is substantial evidence that the vascular effects of
SMN are mediated by activation of the NO/cyclic
uanosine monophosphate (cGMP) pathway. Nitrates are
rodrugs that release NO as their pharmacologically active
rinciple (15). This has been demonstrated by measure-
ents of NO release, accumulation of cGMP, and activa-
ion of protein kinase G, and holds true for a variety of
tructurally very diverse compounds including ISMN,
hich all carry one or more aliphatic nitrate moiety (16).
itric oxide can exert a variety of vasoprotective effects such
s vasodilation, antioxidative effects, and inhibition of plate-
et aggregation, leucocyte adhesion, and smooth muscle
roliferation (8). Of these, the antioxidative effects of NO
ppear to be particularly important in our study.
The mechanism by which NO exerts antioxidative effects
s multifactorial. Nitric oxide has been shown to inhibit
eroxidation of lipids such as free fatty acids, phosphatidyl-
holine, and low-density protein particles (17). In a previous
igure 6. Effect of a four months’ lasting oral treatment with isosorbide
ononitrate (ISMN) on vasorelaxations to ISMN. There was a rightward
hift of the ISMN concentration response curve in cholesterol chow
CHOL)-ISMN as compared with controls and with CHOL (*p 
.0001, each). This significantly less vasodilator response to ISMN
ndicates the development of nitrate tolerance in CHOL-ISMN.nvestigation, we have treated hypercholesterolemic rabbits
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August 4, 2004:624–31 Eccentric ISMN and Vascular Oxidative Stressith another organic nitrate (pentaerythritol tetranitrate)
nd found a significant reduction of low-density lipoprotein
xidation that was associated with a preservation of endo-
helial function (18). Another mechanism by which NO
xerts antioxidative effects is stimulation of the expression
nd activity of extracellular superoxide dismutase (ecSOD).
e have recently shown that this effect is initiated by both
xogenous and endogenous NO and that it occurs in vitro
nd in vivo (19). Furthermore, preliminary studies in human
mbilical arteries and veins and in human vascular smooth
uscle cells have indicated that ISMN increases ecSOD
xpression (T. Fukai, G. Kojda, personal communication,
eptember 2004). Antioxidative effects of NO may also
nclude the induction of ferritin and heme oxygenase (20),
nd there is evidence that organic nitrates activate this
athway (21). Thus, the complete reduction of increased
ascular superoxide formation in hypercholesterolemia by
ccentric ISMN is most likely mediated by activation of
ifferent pathways including inhibition of lipid peroxidation
nd induction of ecSOD, ferritin, and heme oxygenase.
Many previous investigations have shown that a variety of
ardiovascular diseases including hypercholesterolemia are
ssociated with both increased vascular superoxide and
ecreased bioavailability of endogenous NO (2). Although
ontroversial findings exist on the direct effects of superox-
de on the atherosclerotic disease process in various trans-
enic animal models (22), it has been well-established that
reduction of vascular superoxide will improve endothelial
unction (6). This coherency has been demonstrated even
efore it was known that the endothelium-derived relaxing
actor is NO (3,4). Thus, the association between reduced
ascular superoxide and improved endothelial function
hown in this study is consistent with previous experimental
nd clinical studies.
Hypercholesterolemia alone inhibited vasorelaxations to
he NO donor SNAP, while additional treatment with
SMN resulted in an improvement of SNAP-induced
asorelaxation. Both effects are likely related to the activity
f soluble guanylyl cyclase (sGC). This key enzyme of the
O/cGMP pathway is extremely sensitive to oxidative
tress and is markedly inhibited by oxidants such as super-
xide and peroxynitrite (23). Previous investigations in
ypercholesterolemic rabbits have shown a reversible in-
rease of expression of a dysfunctional sGC that was
ssociated with inhibition of endothelium-dependent and
NAP-induced vasodilation (24). Thus, the improvement
f SNAP-induced vasodilation in CHOL-ISMN provides
urther evidence for the antioxidative efficacy of the eccen-
ric ISMN treatment. Our observation of an almost un-
hanged vasodilatory response of atherosclerotic aortic rings
o ISMN might be due to the fact that endothelial NO
roduction could impact on the generation of NO from
itrates. We have reported that NO inhibits the bioactiva-
ion of glyceryl trinitrate (GTN) by measuring 1,2- and
,3-glyceryl trinitrate concentrations as well as vasodilation vn aortic rings that were subjected to continuous NO before
ncubation with GTN (25).
We found that complete inhibition of increased vascular
uperoxide only partially reduced morphologic and func-
ional sequels of hypercholesterolemia. These results con-
rm that vascular superoxide plays a role in the atheroscle-
otic disease process but suggests at the same time that its
ontribution to the pathogenesis of atherosclerosis is lim-
ted. However, it is likely that vascular superoxide genera-
ion increases when plasma concentrations of ISMN de-
rease in the course of the treatment. For example, in
onatherosclerotic rabbits the plasma concentration of
SMN 3 h after dosing was 1,768 ng/ml but dropped to
4.5 ng/ml 16 h after dosing (26). In addition, there are
ther radicals and/or oxidants such as the hydroxyl radical,
ydrogen peroxide, and peroxynitrite, which are likely
nvolved in the pathogenesis of atherosclerosis (2,27). Thus,
e cannot exclude intermittent increases of vascular super-
xide or the formation of peroxynitrite when ISMN plasma
evels drop. Such a phenomenon might have reduced the
eneficial effect of ISMN in our study.
Previous investigations have shown that the total vascular
OD activity is increased in hypercholesterolemic rabbits
28). Although this might decrease the likelihood of per-
xynitrite formation (29) and the toxic effects of its reaction
roducts such as nitrogen dioxide, thiyl, sulfinyl, and disul-
de radicals (8), it will almost certainly increase the steady-
tate concentration of vascular hydrogen peroxide. Further-
ore, uncoupled eNOS produces superoxide and NO in
ery close proximity and might increase vascular oxidative
tress without increasing total vascular superoxide formation
6). Although aortic generation of NO from tissue ISMN as
easured by GC/MS did not change superoxide detection
y lucigenin (suggesting that peroxynitrite formation from
issue ISMN is unlikely), increased vascular radicals and/or
xidants other than superoxide are likely involved in intimal
esion formation and endothelial dysfunction in CHOL-
SMN.
Increased vascular superoxide in hypercholesterolemia
ad apparently little impact on the vasodilator activity of
SMN, but we observed a moderate nitrate tolerance in
HOL-ISMN where superoxide was not increased as
ompared with controls. This confirms our previous find-
ngs on nitrate tolerance induced by eccentric ISMN (26)
nd provides further evidence for multifactorial mechanism
f in vivo nitrate tolerance that includes superoxide-
ependent (30) and -independent pathways (26). An eccen-
ric dosing regimen for ISMN as used in our previous study
ad no effect on vascular superoxide but initated nitrate
olerance when its minimal plasma concentrations reached a
hreshold 14.5  4 ng/ml.
Recently, it has been demonstrated that the extent of
ndothelial dysfunction predicts acute coronary events in
oronary artery disease (31). This finding suggests that an
mprovement of endothelial function (e.g., by reducing
ascular superoxide) may delay the atherosclerotic disease
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Eccentric ISMN and Vascular Oxidative Stress August 4, 2004:624–31rocess. In this context, one may speculate on potential
linical implications of our results. We have shown previ-
usly that pentaerythrithyl tetranitrate inhibits the induc-
ion (12) and the progression (18) of atherosclerosis in
ypercholesterolemic rabbits. It has been reported that the
holesterol-fed rabbit produces atherosclerotic lesions,
hich are quite similar to human atherosclerosis (32). This
ay suggest some clinical relevance of our results, although
nimal experiments have significant limitations. A recently
ublished large clinical trial has shown that nicorandil,
hich predominantly acts as a nitrovasodilator but also
pens potassium channels (33–35), can improve the out-
ome of patients with stable angina pectoris and additional
isk factors by reducing major coronary events (36). This
uggests that the nitrate-like activity of nicorandil contrib-
ted to its prognostic effect.
Although we used a high dose of ISMN, which initated
itrate tolerance even at eccentric dosing, we believe that the
esults of our study add another piece of evidence on
otentially inhibitory effects of nitrates on the development
f atherosclerosis. To achieve this effect, it is obviously
mportant to avoid severe nitrate tolerance, as inducible with
ontinuous nitroglycerine (30), by strictly adhering oral
itrate therapy to the recommended intermittent dosing
egimen (10). Finally, a randomized placebo-controlled
rospective clinical investigation is needed to elucidate the
ffects of organic nitrates on prognosis in the setting of
uman atherosclerosis.
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